Susquehanna International Group
CATX icon

Susquehanna International Group’s Perspective Therapeutics CATX Stock Holding History

Susquehanna International Group’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Buy
+51,100
New +$216K ﹤0.01% 11562

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's CATX Position: Q1 2026 in Review

Susquehanna International Group increased its Perspective Therapeutics (CATX) stake by 129% in Q1 2026, buying an estimated $444K and bringing the position to 186,630 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #8539.

Susquehanna International Group first reported a position in CATX in Q2 2014 and has held it in 27 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Susquehanna International Group held 186,630 shares of Perspective Therapeutics worth $778K as of Q1 2026.
  • Susquehanna International Group bought 105,189 Perspective Therapeutics shares in Q1 2026, an estimated $444K.
  • Perspective Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8539 holding.
  • Susquehanna International Group first reported a position in Perspective Therapeutics in Q2 2014 and has held it in 27 quarters since.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.